EloraTZP: Eloralintide + Tirzepatide Phase 2b Results (2026)
Reviewed by
Brandon Johnson — Certified Personal Trainer, Nutrition Coach & Peptide Research Consultant
Brandon Johnson is a certified personal trainer, nutrition coach, and peptide research consultant with a background in kinesiology and over 15 years of experience in fitness and wellness. He reviews all PSPeptides educational content for scientific accuracy and practical relevance.
EloraTZP is Lilly’s pairing of eloralintide with tirzepatide, and in its 48-week Phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes the top combination, eloralintide 9 mg plus tirzepatide 15 mg once weekly, produced a −23.3% body-weight change (−54.1 lb) against −3.0% for placebo and −14.8% for tirzepatide 15 mg alone. Every arm, every dose pairing and every caveat from that trial is set out below.
Both halves of the combination matter for status: eloralintide is investigational and not approved by any regulator as of October 2026, and the EloraTZP pairing has only been tested as two separate injections, with a co-formulation planned for Phase 3 but not yet tested in people (Lilly press release, Sept 30, 2026). The eloralintide 10 mg research vial is supplied for laboratory use, and this article reports what the combination trial found; it is not a treatment guide.
The reason researchers care is mechanistic: eloralintide works through the amylin receptor and tirzepatide through the GIP and GLP-1 receptors, so the pairing adds a second pathway rather than a higher dose of the first. The eloralintide vs tirzepatide comparison covers the molecules separately; this page covers what happened when the trial put them together.
EloraTZP at a Glance
| Item | What the Phase 2b trial reported (October 2026) |
|---|---|
| What it is | Eloralintide (amylin receptor agonist) plus tirzepatide (GIP/GLP-1 receptor agonist), each once weekly |
| Trial | NCT06603571; Phase 2b; 48 weeks; double-blind, placebo-controlled; US and Argentina |
| Population | 367 adults with obesity or overweight and type 2 diabetes |
| Administration | Two separate once-weekly injections; co-formulation not yet tested |
| Pairings studied (eloralintide + tirzepatide) | 3 mg + 5 mg; 6 mg + 5 mg; 6 mg + 10 mg; 9 mg + 15 mg |
| Top result | −23.3% (−54.1 lb) at 9 mg + 15 mg, efficacy estimand |
| Reference arms | Tirzepatide 15 mg alone −14.8%; placebo −3.0% |
| Discontinuation for adverse events | Combination arms 10.8–27.0%; eloralintide alone 0–10.8%; tirzepatide 15 mg 2.9%; placebo 16.7% |
| Status | Investigational; Phase 3 studies of a co-formulation planned by the end of 2026 |
| Research format | Eloralintide 10 mg lyophilized vial plus a separate tirzepatide vial |
Source: Lilly press release, Sept 30, 2026 (NCT06603571); Lilly, “What to know about eloralintide” (September 2026).
Two rows of that table govern how every number on this page should be read. The population had type 2 diabetes, where weight-loss figures run lower than in non-diabetic trials, so none of these results can be set against SURMOUNT-1 or against eloralintide’s own Phase 2; and the regimen was two injections, so nothing here describes a co-formulated product.

Two Injections, One Regimen: How the Phase 2b Trial Was Built
Lilly reported the trial on September 30, 2026 at EASD in Milan. It randomised 367 adults with type 2 diabetes and obesity or overweight, at sites in the US and Argentina, to 48 weeks of double-blind, placebo-controlled treatment, with the two peptides injected separately once a week rather than as a single product.
Nine arms were run: four pairings, three eloralintide-alone doses (3, 6 and 9 mg), tirzepatide 15 mg alone, and placebo. That design is what makes the EloraTZP dataset unusually useful: the monotherapy arms sit inside the same trial, population and 48 weeks as the pairings, so within-trial comparisons are legitimate in a way that cross-trial ones are not.
The co-formulation that Lilly intends to take into Phase 3 by the end of 2026 would deliver both peptides in one injection, and it has not yet been tested in people (Lilly, What to know about eloralintide); everything below therefore describes the two-injection regimen.
All Nine Arms: Week-48 Weight Change in Type 2 Diabetes
| Arm | Eloralintide (weekly) | Tirzepatide (weekly) | Week-48 weight change, efficacy estimand |
|---|---|---|---|
| Combination | 9 mg | 15 mg | −23.3% (−54.1 lb) |
| Combination | 6 mg | 10 mg | −19.9% |
| Combination | 6 mg | 5 mg | −19.4% |
| Combination | 3 mg | 5 mg | −13.2% |
| Tirzepatide alone | — | 15 mg | −14.8% |
| Eloralintide alone | 3 mg | — | −8.2% |
| Eloralintide alone | 6 mg | — | −12.3% |
| Eloralintide alone | 9 mg | — | −11.1% |
| Placebo | — | — | −3.0% |
Week-48 figures from the Lilly press release of Sept 30, 2026; NCT06603571, 367 participants, all with type 2 diabetes, efficacy estimand.
The ordering is consistent at the top: every pairing that included at least 6 mg of eloralintide finished below −19%, and the 9 mg + 15 mg arm finished at −23.3%, where tirzepatide 15 mg alone in the same trial finished at −14.8%. Because those arms share a trial, a population and a duration, the gap between them is a within-trial observation rather than an indicative cross-trial one.
The eloralintide-alone arms deserve a careful read. At 3, 6 and 9 mg they produced −8.2%, −12.3% and −11.1%, with 9 mg numerically below 6 mg; nine arms share 367 participants, so each arm is small and a gap of that size is noise. The figures also sit well below the −12.4%, −17.6% and −20.1% that the same doses produced over 48 weeks in the non-diabetic Phase 2 trial (Lilly press release, Nov 6, 2025), which reflects the population difference rather than a contradiction.
That is also why the −14.8% tirzepatide arm cannot be compared with the −22.5% that 15 mg produced over 72 weeks, on the same efficacy estimand, in SURMOUNT-1’s 2,539 participants without type 2 diabetes (Jastreboff et al., N Engl J Med 2022; Lilly press release, Apr 28, 2022): different population, different duration, different trial. The SURMOUNT figure serves only to mark the tirzepatide number in the EloraTZP trial as a diabetic-population, 48-week result.

The Four Dose Pairings and What Each Added
Four EloraTZP pairings were studied, and the pattern across them is more informative than the headline. Eloralintide 3 mg with tirzepatide 5 mg produced −13.2%, against −8.2% for 3 mg of eloralintide alone; raising eloralintide to 6 mg with the same 5 mg of tirzepatide produced −19.4%, and doubling tirzepatide to 10 mg alongside 6 mg of eloralintide moved the result only to −19.9%.
The 9 mg + 15 mg pairing, the highest dose of each, gave −23.3% (−54.1 lb), while 9 mg of eloralintide alone gave −11.1% and 15 mg of tirzepatide alone gave −14.8%. Read together, the pairings hint that the eloralintide component carried much of the step from 3 mg to 6 mg, while the tirzepatide dose mattered less between 5 and 10 mg; with small arms, that is a hypothesis for research, not a conclusion.
No eloralintide dose above 9 mg and no tirzepatide dose below 5 mg was paired, and Lilly’s release does not report the escalation schedule used to reach each pairing. The eloralintide dosage guide sets out the monotherapy escalation schemes from Phase 2, which remain the only published eloralintide titration data.
Why an Amylin Agonist Adds to a GIP/GLP-1 Agonist
Eloralintide is designed to preferentially activate the amylin 1 receptor, whereas tirzepatide acts at the GIP and GLP-1 receptors; the pathways are distinct, so pairing them is a mechanistic addition rather than a dose increase. The trial’s own arms show that addition in a diabetic population: tirzepatide 15 mg alone −14.8%, eloralintide 9 mg alone −11.1%, both together −23.3%.
The precedent is CagriSema, which combines the amylin analogue cagrilintide with semaglutide. In REDEFINE 1, 3,417 adults without type 2 diabetes lost −20.4% over 68 weeks on cagrilintide 2.4 mg plus semaglutide 2.4 mg against −3.0% on placebo (Garvey et al., N Engl J Med 2025); in REDEFINE 2, 1,206 adults with type 2 diabetes lost −13.7% against −3.4% (Davies et al., N Engl J Med 2025). The spread between those two results shows the same population effect that shapes the EloraTZP numbers.
Our CagriSema vs semaglutide comparison covers that program. The Lilly pairing swaps the partner on each side, tirzepatide for semaglutide and eloralintide for cagrilintide; the tirzepatide research guide covers the incretin half of that swap, and the comparison linked in the introduction covers the amylin half.

Tolerability: Discontinuation for Adverse Events by Arm Type
Discontinuation for adverse events is the only tolerability measure in Lilly’s release, and it is given by arm type rather than by individual arm. That limits what can be said about any single pairing, but the ranges are still informative when read against the monotherapy arms of the same trial.
| Arm type (48 weeks, type 2 diabetes) | Discontinued for adverse events | Note |
|---|---|---|
| EloraTZP combination arms (four pairings) | 10.8% to 27.0% | Range across pairings; per-pairing values not reported |
| Eloralintide alone (3, 6 and 9 mg) | 0% to 10.8% | Range across the three doses |
| Tirzepatide 15 mg alone | 2.9% | Single arm |
| Placebo | 16.7% | Single arm |
| Context: eloralintide Phase 2 monotherapy, pooled (48 weeks, no type 2 diabetes) | 10.1% (placebo 7.7%) | Different trial and population; indicative only |
Sources: Lilly press release, Sept 30, 2026 (EloraTZP Phase 2b); Billings et al., The Lancet 2025 (Phase 2 monotherapy context, safety population N=260).
Two readings follow. The upper end of the combination range, 27.0%, is well above anything seen on either drug alone in this trial, and the placebo figure of 16.7% is itself high, which widens the uncertainty around every arm. Without per-pairing values, which pairing sat at the top of the range cannot be said.
What is missing matters as much: nausea, vomiting and fatigue by arm are not in Lilly’s release, so the escalation-and-nausea analysis that exists for eloralintide monotherapy, covered in the eloralintide side-effects review, has no combination equivalent yet.
What the Combination Data Do Not Show
Because the Phase 2b trial is the only human dataset for EloraTZP, its boundaries define what can be said as of October 2026. The gaps are listed plainly so that no protocol is built on an assumption the data do not support.
- No non-diabetic data: every participant had type 2 diabetes, so no published figure exists for the combination in people without it.
- No co-formulation data: the two peptides were injected separately, and the single-injection product planned for Phase 3 has not been tested in people.
- No data with other partners: no human study has combined eloralintide with retatrutide, semaglutide or cagrilintide.
- No per-pairing tolerability: discontinuation is a range across the four combination arms, and nausea by arm is not reported.
- No escalation detail: how each arm reached its final doses is not reported.
- No data beyond 48 weeks and no Phase 3 result for the monotherapy or the combination.
The last point also fixes the regulatory picture. Neither eloralintide nor the combination has an announced filing or approval date as of October 2026, and the eloralintide research guide lists every dated milestone that does exist, from the Phase 2 publication to the Phase 3 completion estimates.

Status in October 2026: Phase 2b Reported, Co-Formulation Phase 3 Planned
As of October 2026 the combination has one reported human trial, the 48-week Phase 2b, and one stated plan: Lilly intends to initiate Phase 3 studies of an EloraTZP co-formulation product by the end of 2026. No Phase 3 doses, readout dates or filing plans have been disclosed for it, and the monotherapy Phase 3 program has no announced filing date either.
The four pairings above are the only dose combinations with human data, and no pairing of eloralintide with a different incretin has any, which is why the FAQ below answers the retatrutide and semaglutide question with a plain no.
Eloralintide and Tirzepatide at PSPeptides
PSPeptides supplies eloralintide as a single 10 mg lyophilized vial and stocks tirzepatide separately. Both are synthesized in a cGMP-compliant facility in Temecula, California, and independent accredited laboratories test each lot: HPLC purity at a 99%+ minimum, mass-spectrometry identity, and endotoxin, sterility, heavy-metal and fentanyl screens, as set out on the certifications page.
Bacteriostatic water, U-100 insulin syringes and the free peptide calculator cover the reconstitution side for any volume. The eloralintide product page carries the current price and publishes each lot’s certificate of analysis; orders placed before 2 PM EST ship the same day, free within the US, and can be paid by card, Afterpay or Klarna.
Frequently Asked Questions About Eloralintide With Tirzepatide
Were eloralintide and tirzepatide given as one injection in the trial?
No. In the 48-week Phase 2b trial the two peptides were given as separate once-weekly injections, and the single-injection co-formulation that Lilly plans to take into Phase 3 by the end of 2026 has not yet been tested in people.
How much weight loss did the combination produce at 48 weeks?
The top EloraTZP pairing, eloralintide 9 mg plus tirzepatide 15 mg, produced a −23.3% body-weight change (−54.1 lb) against −3.0% for placebo in adults with obesity or overweight and type 2 diabetes. The other pairings gave −19.9% (6 mg + 10 mg), −19.4% (6 mg + 5 mg) and −13.2% (3 mg + 5 mg), with tirzepatide 15 mg alone at −14.8%.
Why can the tirzepatide arm not be compared with SURMOUNT-1?
Because the populations and durations differ. The EloraTZP trial enrolled people with type 2 diabetes and ran 48 weeks, so its −14.8% for tirzepatide 15 mg is a diabetic-population figure, whereas SURMOUNT-1’s −22.5% at 15 mg came from 2,539 participants without type 2 diabetes over 72 weeks. Weight-loss figures run lower in diabetic populations, so only within-trial comparisons are fair.
Has eloralintide been combined with retatrutide or semaglutide?
No. As of October 2026 no human study has combined eloralintide with retatrutide, semaglutide or cagrilintide; tirzepatide is the only partner with published data. A protocol pairing eloralintide with any other incretin would have no clinical template for doses, sequencing or tolerability.
References
- Eli Lilly press release, Sept 30, 2026 — “Lilly’s EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction…” https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
- Eli Lilly, “What to know about eloralintide” (last updated September 2026). https://www.lilly.com/news/stories/what-to-know-about-eloralintide
- Eli Lilly press release, Nov 6, 2025 — “Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight.” https://investor.lilly.com/node/53246
- Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. https://doi.org/10.1016/S0140-6736(25)02155-5
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
- Eli Lilly press release, Apr 28, 2022 — “Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1.” https://investor.lilly.com/node/47141
- Garvey WT, et al. REDEFINE 1 (N Engl J Med 2025, https://doi.org/10.1056/NEJMoa2502081) and Davies MJ, et al. REDEFINE 2 (N Engl J Med 2025, https://doi.org/10.1056/NEJMoa2502082).
All PSPeptides products are sold exclusively for research and laboratory use.